These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38622938)

  • 21. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
    Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Higher third-generation cephalosporin prescription proportion is associated with lower probability of reducing carbapenem use: a nationwide retrospective study.
    Muller A; Bertrand X; Rogues AM; Péfau M; Alfandari S; Gauzit R; Dumartin C; Gbaguidi-Haore H;
    Antimicrob Resist Infect Control; 2018; 7():11. PubMed ID: 29387345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013.
    Guh AY; Bulens SN; Mu Y; Jacob JT; Reno J; Scott J; Wilson LE; Vaeth E; Lynfield R; Shaw KM; Vagnone PM; Bamberg WM; Janelle SJ; Dumyati G; Concannon C; Beldavs Z; Cunningham M; Cassidy PM; Phipps EC; Kenslow N; Travis T; Lonsway D; Rasheed JK; Limbago BM; Kallen AJ
    JAMA; 2015 Oct; 314(14):1479-87. PubMed ID: 26436831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Outcomes and Treatment Strategies in Patients With Non-Carbapenemase-producing Carbapenem-Resistant Versus Carbapenem-Susceptible Enterobacterales Infections.
    Debnath A; Pillinger KE; Martin AJ; Dobrzynski D; Cameron A; Shulder S
    Ann Pharmacother; 2023 Jul; 57(7):803-812. PubMed ID: 36268974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors and molecular epidemiology of fecal carriage of carbapenem resistant Enterobacteriaceae in patients with liver disease.
    Tian F; Li Y; Wang Y; Yu B; Song J; Ning Q; Jian C; Ni M
    Ann Clin Microbiol Antimicrob; 2023 Jan; 22(1):10. PubMed ID: 36710337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical characteristics of carbapenem-resistant
    Sun Y; Zheng H; Zhang JL; Yu LX; Wang B; Gao W; Cai JZ; Liu YH
    Zhonghua Er Ke Za Zhi; 2020 Aug; 58(8):640-645. PubMed ID: 32842384
    [No Abstract]   [Full Text] [Related]  

  • 29. Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
    Kim NH; Han WD; Song KH; Seo HK; Shin MJ; Kim TS; Park KU; Ahn S; Yoo JS; Kim ES; Kim HB
    Am J Infect Control; 2014 Dec; 42(12):1270-3. PubMed ID: 25465255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Colonization with extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) and carbapenem-resistant Enterobacterales (CRE) in healthcare and community settings in Botswana: an antibiotic resistance in communities and hospitals (ARCH) study.
    Mannathoko N; Mosepele M; Gross R; Smith RM; Alby K; Glaser L; Richard-Greenblatt M; Dumm R; Sharma A; Jaskowiak-Barr A; Cressman L; Sewawa K; Cowden L; Reesey E; Otukile D; Paganotti GM; Mokomane M; Lautenbach E
    Int J Infect Dis; 2022 Sep; 122():313-320. PubMed ID: 35688308
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae.
    Predic M; Delano JP; Tremblay E; Iovine N; Brown S; Prins C
    Am J Infect Control; 2020 Sep; 48(9):1028-1031. PubMed ID: 31924388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustaining Antimicrobial Stewardship in a High-Antibiotic Resistance Setting.
    Ng TM; Heng ST; Chua BH; Ang LW; Tan SH; Tay HL; Yap MY; Quek J; Teng CB; Young BE; Lin R; Ang B; Lee TH; Lye DC
    JAMA Netw Open; 2022 May; 5(5):e2210180. PubMed ID: 35503216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and molecular characteristics and risk factors for patients acquiring carbapenemase-producing and non-carbapenemase-producing carbapenem-nonsusceptible-Enterobacterales bacteremia.
    Wu AY; Chang H; Wang NY; Sun FJ; Liu CP
    J Microbiol Immunol Infect; 2022 Dec; 55(6 Pt 2):1229-1238. PubMed ID: 34824020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 - 2020: An update.
    Lowe M; Shuping L; Perovic O
    S Afr Med J; 2022 Aug; 112(8):542-552. PubMed ID: 36214398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T; Okonogi S
    J Infect Public Health; 2024 May; 17(5):727-734. PubMed ID: 38513335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
    Ng TM; Teng CB; Lye DC; Apisarnthanarak A
    Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship.
    Marchaim D; Chopra T; Bhargava A; Bogan C; Dhar S; Hayakawa K; Pogue JM; Bheemreddy S; Blunden C; Shango M; Swan J; Lephart PR; Perez F; Bonomo RA; Kaye KS
    Infect Control Hosp Epidemiol; 2012 Aug; 33(8):817-30. PubMed ID: 22759550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes and Risk Factors for Carbapenem-resistant Enterobacterales Bloodstream Infection in Solid Organ Transplant Recipients.
    Anesi JA; Lautenbach E; Thom KA; Tamma PD; Blumberg EA; Alby K; Bilker WB; Werzen A; Ammazzalorso A; Tolomeo P; Omorogbe J; Pineles L; Han JH
    Transplantation; 2023 Jan; 107(1):254-263. PubMed ID: 35856636
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia.
    Farzana R; Jones LS; Rahman MA; Sands K; van Tonder AJ; Portal E; Criollo JM; Parkhill J; Guest MF; Watkins WJ; Pervin M; Boostrom I; Hassan B; Mathias J; Kalam MA; Walsh TR
    Clin Infect Dis; 2023 Jan; 76(1):119-133. PubMed ID: 35412593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.